Cargando…
Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis
The meta-analysis aimed to assess the clinical efficacy of chemotherapeutic triplet‐drug regimen combined with anti‐EGFR antibody in patients with initially unresectable metastatic colorectal cancer (mCRC). A systematic literature search was performed in PubMed Publisher. Studies evaluating FOLFOXIR...
Autores principales: | Tian, Muyou, Li, Huifen, Dong, Wenjing, Li, Yuhong, Jiang, Ting, Lv, Yanhua, Zeng, Jianxiong, Jiang, Xiaomei, Yin, Zhaofeng, Xiao, Jianjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656984/ https://www.ncbi.nlm.nih.gov/pubmed/37978547 http://dx.doi.org/10.1186/s12957-023-03256-7 |
Ejemplares similares
-
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
por: Elshenawy, Mahmoud A., et al.
Publicado: (2020) -
Long non-coding RNA (FALEC) promotes malignant behaviors of gastric cancer cells by regulating miR-203b/PIM3 axis
por: Dong, Wenjing, et al.
Publicado: (2022) -
Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis
por: Wu, Qian, et al.
Publicado: (2022) -
Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma
por: Ranganathan, Sarangarajan, et al.
Publicado: (2016) -
Programmed Chemotherapy for Patients with Metastatic Unresectable Gastric Cancer
por: Shinoda, Masataka, et al.
Publicado: (2012)